← Back to Search

Diagnostic Imaging

Developmental dysplasia of the hip (DDH) for Developmental Dysplasia of the Hip

N/A
Waitlist Available
Led By Paul Beaule, MD, FRCSC
Research Sponsored by Ottawa Hospital Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* patients with a diagnosis of developmental dysplasia of the hip (DDH)
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Summary

One of the leading causes of hip arthritis is developmental dysplasia of the hip (DDH). DDH can lead to major damage in the hip joint and may result in hip arthritis later in life. Patients recruited into this study will be undergoing corrective hip surgery within the next 6 months with a goal of preventing further hip problems down the road. This study is being done to see how well a newer type of Magnetic Resonance Imaging (MRI) detects hip cartilage damage compared to an older but well validated MRI method.

Eligible Conditions
  • Developmental Dysplasia of the Hip

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Assess proteoglycan amounts in hip cartilage
Secondary study objectives
Change in WOMAC Questionnaire
Change in iHOT 12 Questionnaire

Side effects data

From 2017 Phase 4 trial • 12 Patients • NCT01895959
8%
knee pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Treatment

Trial Design

1Treatment groups
Experimental Treatment
Group I: Developmental dysplasia of the hip (DDH)Experimental Treatment1 Intervention
Patients will complete 2 magnetic resonance imaging (MRI): T1-rho and dGEMRIC. The T1-rho MRI does not require the injection of a contrast agent, while the dGEMRIC MRI requires a gadolinium injection to visualize cartilage in the hip.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Magnetic Resonance Imaging (MRI)
2015
Completed Phase 4
~1800

Find a Location

Who is running the clinical trial?

Zimmer BiometIndustry Sponsor
373 Previous Clinical Trials
67,093 Total Patients Enrolled
7 Trials studying Developmental Dysplasia of the Hip
1,491 Patients Enrolled for Developmental Dysplasia of the Hip
Ottawa Hospital Research InstituteLead Sponsor
572 Previous Clinical Trials
2,788,997 Total Patients Enrolled
2 Trials studying Developmental Dysplasia of the Hip
262 Patients Enrolled for Developmental Dysplasia of the Hip
The Ottawa Hospital Academic Medical AssociationOTHER
22 Previous Clinical Trials
2,871 Total Patients Enrolled
~3 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top